Aurora Cannabis is currently working on building up accounts as it is looking forward to legalizing cannabis edibles and CBD infused products at the federal level the following winter season. However, it won’t be intruding its sale growth and work for making it profitable.
Aurora Cannabis plays a huge role in the industry because of certain reasons. It is a Medical Marijuana producer and supplier from Canada with little to no alternatives in the uprising industry. Secondly, it’s expected collaboration with Coca Cola is paving way for more popularity among the general public. Also, it has partnerships with intelligent brands who are working on technology that will cost less for more yield. All these factors synergistically act well together in making Aurora Cannabis the leading player in the industry so far.
The company is hoping to grow around twenty five thousand kilograms by the end of June this year. However, there will be a confidential amount of stock not available for sale in the market.
The finance management team of the brand is trying to instill advanced skills in the staff as the industry went through a number of challenges in the previous year.
Aurora Cannabis has been setting its eye on setting reforms in its revenue
With the start up launch of new products from the legalization, there will be a smoother road to drive on. It ultimately inspired the management to be shifting towards the idea of taking a minute quantity of revenue and placing it into the inventory. This way they will be able to invest into innovative products that will emerge in the industry.
There have been some obstacles in the way due to shortage in supplies and inactive launching of retail marijuana stores in Canada since October 2018. Ottawa has presumed that legalization of cannabis edibles, CBD infused products and other concentrates will occur this fall. However, the precise timing and the number is not yet disclosed by any representative. At this stage, Aurora is aiming to build up stocks comprising off all kinds of varieties in infused products, vape pens and edibles. They are also planning to incorporate a range of CBD beverages once the market has set up and gone to a larger scale.
Aurora has increased its production
In the later half of the quarter, Aurora increased its production for up to two times with a stock of 15,590 kg. Much of the cultivation was done in the same time. It took the overall capacity of the organization to an impressive level of 150,000 kg on annual scale.
The total revenue climbed to $29.6 million which counted as a 37 percent increase in the value. This exceeds the total medical revenue of $29.1 million. The price per gram of the dried items decreased down from $1.92 to $1.42. however, the average net selling cost decreased in addition to it to the final value of $6.40 per gram.
More companies like Aurora are looking up for ways and measures to spark up their production capacity of their products to stand as a big name in the industry. With Aurora having figured that issue out, it looks like they are already prepared for the big game.
The company faced some losses in the past year
However, things haven’t been always smooth for them as Aurora faced a $158-million loss on their revenue of $65 million in the spring of last year.
It is apparent that the shareholders are also looking forward to its increased production capacity as a way to standout in the market.
The maximum demand in the industry is somewhat not traceable up to this point. However, the Canadian market offers a big space for companies having the potential to grow. Experts claim that in the future, there is a big opportunity for Canada to import its cannabis products to other countries.
Colorado’s sale of recreational cannabis has outpaced the sale of medical cannabis
In Colorado, in 2018, the legal sale of recreational cannabis has outpaced the sale of medical cannabis. And this has become a new milestone for the state.
Recreational cannabis was sold twice higher than the medical market in 2018
Colorado’s Marijuana Enforcement Division (MED) has stated that the medical market has sold about 147,863 lbs. of buds last year. While the sale of recreational cannabis was about 288,292 lbs. of buds. That is twice the amount of medical cannabis.
For comparison, in 2017, the sale of recreational marijuana was 238,149 lbs. Whereas the users have bought only 172,994 lbs. of buds from the medical market.
It shows that Colorado’s sale of recreational cannabis has outpaced the sale of medical cannabis. And in one year, the gap in the sale of both markets has increased by 73%. In total, both markets have sold 446,155 lbs. of cannabis in 2018, and 411,143 lbs. in the year 2017.
In 2014, Colorado opened the first market for sailing recreational cannabis (adult-use market). Continuous expansion in this market can be a reason for an increase in the sale of recreational marijuana. In the first year, the sale of medical cannabis was higher than that of the adult-use market.
In 2015, the adult-use market sold about 38,660 lbs. While the sale of the medical market was 109,578 lbs. In 2016, sales from both markets got equal. But in 2017, the adult-use market has represented a 58% share in the sale of legal marijuana. That has increased up to 66% by last year.
Registration and renewal fee for the medical card has made medical cannabis costly and promoted the use of recreational cannabis
The MED has found a 3% increase in the licenses (47 licenses) of recreational cannabis facilities. In contrast, the licenses of the medical market have decreased by 8%.
The MED report has also shown that for the people buying edibles, the adult-use market is the primary target. 86% of the edibles come from this market. And during July – December 2018, this market has used 75% of the grown cannabis.
A study has found that many buyers at adult-use cannabis shops are using cannabis for the same reason as that of registered patients. These reasons may include reducing pain or sleep issues.
The number of medical patients has declined with the increase in the adult-use market. This change is common across the country. The people who used to ask for medical cannabis may not renew their registration after the opening of the recreational shops.
Also read- Colorado’s New Deal in Cannabis Market
The process of the medical card has also made medical cannabis costly. Many patients may leave the medical programs because they also have to pay registration or renewal fee for a medical card with the price for cannabis.
Another issue that may lead to this market shift is access to some specific products. Products with high THC content have more demand in the market. But these may not benefit the medical market.
The latest MED reports have also suggested that the buyers in both markets have more interest in concentrates. Such products carry a high price in the adult-use market.
All of the above data shows that Colorado’s sale of recreational cannabis has outpaced the sale of medical ones. And with an increase in the adult-use market, Colorado should also provide benefits to the patient to keep medical programs active.
Dispensaries Funding in Missouri
Medical cannabis dispensaries had to pay $3.9 million fees to the concerning bodies of the state in Missouri. This has happened in the mid of June 2019.
Cannabis business applications are 543 in total. Moreover, St. Louis and Kansas City regions received 180 applications in total for opening cannabis dispensaries.
Moreover, Missouri will start accepting these applications from August 3. However, it has permitted groups to give associated fees of ten thousand dollars for cultivation. It has also allowed a fee of six thousand dollars to sell it. The same fees apply for cannabis derivative items.
Furthermore, the data of the applicants will be confidential according to the decision of the state. A judge last week granted a motion for the enforcement to force Missouri to release those records. However, it postponed the tentative date for the judgment summary to give time to the state for their final decision.
Missouri is the 33rd state to be legalizing cannabis for medical uses. The win constituted a percentage of 65 percent in total for Amendment 2. This led to people in business from the state to pour in huge amounts of money for the ever emerging industry.
Retailers looking forward for next year
Retailers will be introducing new lines of cannabis-infused products next year. Furthermore, the data predictions state this top up by hundred million dollars after six years.
Health care funds for incoming veterans will be requiring licensing fees and tax proceedings. Predictions suggest they will be generating around twenty million dollars annually.
People who wrote their applications have made long term planning regarding their businesses. Also, they are in anticipation of a competitive procedure for entering the legal industry.
Applications are available this summer
Application forms have been available since June 4. However, the dates for accepting business applications are from August 3 to August 17. Missouri will hopefully begin providing licenses to the businesses at the end of the year.
However, the overall proceeding will be too much costly and time taking for the applicants. It includes security and economic influence as well with the provision of business details. Sixty-nine applicants for the dispensary solely belonged to Jackson County.
The remaining applicants were twenty-one and fourteen for cannabis cultivation and infusion products, respectively.
Status of applicants in different regions of Missouri
St. Louis County had 51 people applying for dispensaries and 17 people for cultivation. The congress district in the US determines the number of dispensaries.
Missouri can approve more than 60 cultivators, 86 companies for cannabis-infused products, and 192 licenses.
Forty-eight dispensaries come this way in the St. Louis metropolitan region. Missouri counties will be getting some dispensaries for two congress districts that extend to Jefferson City.
What are some major concerns regarding cannabis business
Missouri will be licensing ten medical cannabis testing facilities. Female business owners are concerned about the state of the industry are more than half white males. It points towards unsettled discrimination in the nation.
Applicants relating to business are concerned about the insiders belonging to other states. They would be cutting the locals out from a big share of the industry.
Cannabigerol and Other Cannabis Compounds
There is a very little knowledge about newly found cannabis compounds that include cannabigerol (CBG) or cannabichromene (CBC).
It becomes difficult to comprehend their benefits due to lack of enough insight on the subjects. It is not surprising that they can potentially benefit as efficient pharmaceutical active compounds. Current standing of the market in understanding the role of other active ingredients is also negligible.
According to experts, the current market is not in favor of advocating any compounds of cannabis other than THC and CBD. However, there is ample room for funding for research once the US government legalizes it on a federal scale.
Pharmaceutical companies are more likely to invest their dollars on finding the benefits of the active compounds. This is a good opportunity for them to make good profits.
However, few production units and extracting brands and units like MediPharm Labs and Valens GroWorks are doing the job. They are incorporating the active ingredients of cannabis into making different products. These include edibles, concentrates, serums, lotions, and ingestibles at the end of the year.
Role of production units in synthesizing products
Production units relating to cannabis are of a different opinion. They think that cannabis manufacture in lab premises can be a slur for the whole culture of consumers. However, some experts predict that it will not be a loss for the market.
This is because of the reason that the demand for the emerging industry is ever growing and is not settling down anytime soon.
The trend is picking up speed and is boosting up among the consumers. Especially there is a lot of potential for synthetic active ingredients of cannabis in the Canadian market than any other market.
Scientists and medical practitioners highly agree to the fact that the application of cannabinoids in pharmaceutical products will influence many aspects. These include other active ingredients which are yet to be studied in detail.
Some people are not in favor of using the substance after cultivating it merely for big pharmaceutical companies. The debate, however, will conclude on legalization at the federal level. Accessibility of cannabis products at domestic level is not that readily available. There is a need for more research on active ingredients.
Opinion of people
Many people want to consume cannabis just for recreational purposes. To add further, if the product becomes so readily available in every home in every room, chances are it is going to lose its essence just like any other generic painkiller did. The question still remains unanswered on the uncertainty of the level of usage of the product.
With the advancement of new extraction techniques, it is becoming more possible to identify new cannabis compounds in the cannabis. Moreover, the quest for looking out for ingredients in hemp seeds and crop is also getting more hype with each day.
However, if scientists are able to investigate thoroughly the uses of all important active ingredients of the substance, they will be better able to direct for the creation of precise products specifically designed to deal with certain problems.
Cannabis4 months ago
Research Suggests Cannabis Effective in Treating Endometriosis
Cannabis2 months ago
What are the main advantages of consuming CBD oil?
Cannabis2 months ago
CBD Gummies: How does it work? Benefits, Pricing and Packages
Cannabis4 months ago
How CBD oil works?
Cannabis3 months ago
25 Strong Cannabis Health Claims that are backed by Science
Cannabis4 months ago
Why is Marijuana Getting Popular Among Senior Citizens?
Cannabis2 months ago
What is the impact of marijuana on mental and physical health?
Cannabis2 months ago
Cannabis: A better treatment for Phantom limb pain